Correction: Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma

In this article (Cancer Immunol Res 2014;2:632–42), which appeared in the July 2014 issue of Cancer Immunology Research (1), the panels of Fig. 1 are labeled incorrectly. The grade 4 toxicities should be labeled as A, and the grade 3 toxicities as B; B to G should be labeled C to H. The authors regret this error.